MBX Biosciences gets FDA green light to move second drug into human testing – Indianapolis Business Journal

The U.S. Food and Drug Administration gave the green light to MBX to test a drug for post-bariatric hypoglycemia,  a rare disease and a serious complication of bariatric surgery, the company said Monday.

Related Keywords

Indiana ,United States ,Wellington ,New Zealand General ,New Zealand ,Switzerland ,Indianapolis ,Indiana University ,Swiss ,Eli Lilly ,Kent Hawryluk ,Richard Dimarchi ,Drug Administration ,Assembly Biosciences ,England Associates ,Frazier Life Sciences ,Novo Nordisk ,Marcadia Biotech ,Denmark Based Novo Nordisk ,Precision Endocrine Peptide ,New England Associates ,Norwest Venture Partners ,